IL2 and graft versus host disease: A previous study by Roychowdhury et al. [111] showed that exogenous delivery of high doses (10 ug) of IL-15, but not IL-2, increases the morbidity of GVHD in a CB17-scid mouse humanized with human PBMCs (Hu-PBL-SCID).